CPIG
CBIO

Chicago Partners Investment Group’s Crescent Biopharma CBIO Stock Holding History

Chicago Partners Investment Group’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-200
Closed -$23.4K – 710
2023
Q3 		$23.4K Hold
200
– – ﹤0.01% 648
2023
Q2 		$31.8K Hold
200
– – ﹤0.01% 673
2023
Q1 		$28K Buy
+200
New +$45K ﹤0.01% 656

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Chicago Partners Investment Group's CBIO Position: Q4 2023 in Review

Chicago Partners Investment Group sold out of Crescent Biopharma (CBIO) in Q4 2023, closing a stake of 200 shares — an estimated $23.4K sold.

Chicago Partners Investment Group first reported a position in CBIO in Q1 2023 and held it in 3 quarters. The position peaked at $31.8K in Q2 2023. 58 funds tracked by Wall St. Rank hold CBIO as of Q4 2023.

  • Chicago Partners Investment Group reported no remaining Crescent Biopharma position as of Q4 2023 after selling out during the quarter.
  • Chicago Partners Investment Group sold 200 Crescent Biopharma shares in Q4 2023, an estimated $23.4K.
  • Chicago Partners Investment Group first reported a position in Crescent Biopharma in Q1 2023 and held it in 3 quarters.
  • Chicago Partners Investment Group's Crescent Biopharma position peaked at $31.8K in Q2 2023.
  • 58 funds tracked by Wall St. Rank held Crescent Biopharma as of Q4 2023.

Based on Chicago Partners Investment Group's 13F filing for Q4 2023, filed 23 Feb 2024.